<DOC>
	<DOCNO>NCT01448291</DOCNO>
	<brief_summary>It know use NuvaRing® alters innate inflammatory biomarkers inflammation . Hypothesis : The hypothesis NuvaRing® alter inflammatory biomarkers inflammation , vaginal defensin cytokine level , result overall anti-inflammatory milieu vagina . Specific aim study : 1 . Determine biomarkers inflammation , include defensins cytokine , concentration woman normal vaginal flora ( Nugent Score 0 - 3 ) NuvaRing® use 2 . Determine change integrity cervicovaginal epithelium leukocytic concentration treatment NuvaRing® 3 . Monitor change Nugent score NuvaRing® use 4 . Assess antimicrobial activity vaginal fluid NuvaRing® use 5 . Assess HIV infectivity ex vivo biopsy specimen NuvaRing® use Methods This prospective , open-label , nonrandomized study . Participants serve control . The Clinical Research Center Eastern Virginia Medical School , Norfolk , Virginia , U.S.A. study site .</brief_summary>
	<brief_title>Effect Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring Vaginal Innate Inflammatory Biomarkers</brief_title>
	<detailed_description>1 . To complete specific aim # 1 , investigator use commercially available elisa kit measure human defensins , inflammatory cytokine , anti-inflammatory cytokine vaginal fluid washing collect use NuvaRing . 2 . To complete specific aim # 2 , investigator collect biopsy uterine cervix NuvaRing use . Specimens undergo histopathological measure overall appearance , epithelial integrity , epithelial thickness , leukocyte infiltration , congestion , edema . The investigator quantitate number CD45+ NFkB+ cell use immunohistology cervical epithelium .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>1 . Women ( age 18 45 ) interested use NuvaRing® contraception 3 month , woman risk pregnancy ( i.e . abstinent , tubal sterilization , partner vasectomy ) 2 . Women normal menstrual cycle ( 2135 day ) past three cycle 3 . Women normal pelvic anatomy ( physical exam ) 4 . Negative urine pregnancy test 5 . Normal pap smear within past 12 month 1 . Pregnancy 2 . Current breastfeed 3 . Less 6 week post partum 4 . Current IUD Implanon use 5 . Depot Medroxyprogesterone Acetate use within past 6 month 6 . Current diagnosis uterine infection 7 . Use hormonal contraception within past 30 day 8 . Current cervical dysplasia 9 . Chronic immune suppression 10 . Chronic use immune suppressor steroids 11 . Chronic antibiotic use 12 . Diabetes fast blood glucose &gt; 105 13 . Hysterectomy 14 . Uncontrolled hypertension ( systolic BP≥140/ diastolic BP≥ 90 ) 15 . Migraine headache complicate aura focal neurologic deficit 16 . Menopause 17 . Standard contraindication combine oral contraceptive use ( thrombophilia , active liver disease , active deep venous thrombosis , history thrombosis ) 18 . Use tobacco product ≥ 35 year age 19 . Two symptomatic genital herpes simplex virus ( HSV ) outbreaks past 12 month 20 . Human immunodeficiency virus 21 . Vulvovaginal candidiasis 22 . Trichamonas vaginalis 23 . Neisseria gonorrhea 24 . Chlamydia trachomatis 25 . Bacterial vaginosis 26 . Nugent score 4 great 27 . Use study medication within past 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Nuvaring</keyword>
	<keyword>Vaginal inflammation</keyword>
	<keyword>Bacterial vaginosis</keyword>
	<keyword>Nugent score</keyword>
</DOC>